About CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
CNS Pharmaceuticals Inc is a biotechnology company focused on developing innovative therapies for the treatment of central nervous system (CNS) cancers. The company specializes in formulating and advancing drug candidates that target various forms of brain tumors, aiming to improve treatment options and outcomes for patients faced with challenging diagnoses. Through its research and development efforts, CNS Pharmaceuticals strives to address significant unmet medical needs in the oncology sector, leveraging scientific expertise and novel approaches to bring potential new therapies to market. Read More
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of its "reasonable best efforts" public offering with a single healthcare focused institutional investor for the purchase and sale of 3,952,570 shares of common stock of the Company (the "Common Stock) (or common stock equivalents in lieu thereof), at a purchase price of $1.265 per share of Common Stock. The Company further agreed to issue to the investors Series F Common Stock purchase warrants to purchase up to 3,952,570 shares of Common Stock (the "Series F Warrants"). The Series F Warrants will have an exercise price of $1.14 per share, will be exercisable immediately following the date of their issuance and will expire in five years.
CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval.
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)
Medulloblastoma is a commonly occurring pediatric brain cancer in kids and adolescents. The cancer develops within the cerebellum, the part of the brain responsible for coordinating movement and other functions. These tumors enlarge quickly, can grow into nearby tissues, and in some cases, can metastasize. The variations in these tumors make it challenging to find appropriate treatments.
A team of researchers has leveraged a technique called temporal learning to train an AI system to predict the likelihood of brain cancer recurring in kids diagnosed with gliomas. This AI model uses the magnetic resonance images periodically captured after the kids have received treatment for the gliomas.
Researchers at Ohio State University Medical Center have identified a key enzyme that may be used to combat one of the deadliest types of brain cancer. Known as PGM3, this enzyme plays a critical role in the hexosamine biosynthesis pathway, which contributes to rapid tumor growth through protein and lipid glycosylation. Targeting PGM3 could significantly improve glioblastoma treatment outcomes.
The global market for brain tumor treatments is experiencing significant transformation powered by advances in immunotherapy, personalized medicine and targeted therapy. The market is projected to grow at a 7.2% CAGR to reach $7.15 billion by 2035, according to a report published by Future Market Insights.
A new study has uncovered key drivers of brain cancer growth that could make it possible to predict or even slow down the rate at which these tumors regrow. This could open a new chapter in personalized cancer treatment.
A research team from the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh has developed a new diagnostic tool capable of profiling brain cancers in pediatric patients. Composed of pediatric neurosurgeons and researchers, the team designed a diagnostic platform that uses the body’s natural cancer-fighting immune response to classify pediatric brain tumors.
CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The company is shifting focus to TPI 287, a candidate with orphan drug designation and prior clinical data. With $6.5 million in cash at year-end and an additional $9.9 million raised post-period, CNS expects funding to last through Q1 2026.
New research shows that firefighters diagnosed with gliomas tend to have a particular set of genetic mutations that aren’t so common in individuals engaged in other occupations. In the past, those specific gene mutations had been linked to haloalkane exposure. Haloalkanes are chemicals often used in fire extinguishers and fire retardants.
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy to Lomustine in recurrent GBM.
CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with other anthracyclines, and the safety profile remained favorable. The company plans to continue analysis and explore further development of Berubicin and its pipeline candidate TPI 287 for CNS malignancies.
